Opus Genetics ( ($IRD) ) has shared an update. On December 17, 2025, Viatris Inc., the commercialization partner for Phentolamine Ophthalmic ...
RESEARCH TRIANGLE PARK, N.C., April 07, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (“Opus” or the “Company”) (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene ...
Opus East LLC and Opus West Corp., two of the five independent operating companies of the Opus Group, have filed for bankruptcy protection to help liquidate their portfolios, according to parent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback